Tecan Group AG (XSWX:TECN)

CHF 203 5.5 (2.78%) Market Cap: 2.53 Bil Enterprise Value: 2.50 Bil PE Ratio: 26.16 PB Ratio: 1.87 GF Score: 88/100

Half Year 2024 Tecan Group AG Earnings Call Transcript
Aug 13, 2024

CHF270 (-17.28%)

Earnings
Tecan Group AG at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Half Year 2023 Tecan Group AG Earnings Call Transcript
Aug 15, 2023

CHF362.6 (+7.79%)

Earnings
Full Year 2022 Tecan Group AG Earnings Call Transcript
Mar 14, 2023

CHF385.4 (+3.83%)

Earnings
Tecan Group AG at JPMorgan Healthcare Conference Transcript
Jan 12, 2023
Half Year 2022 Tecan Group AG Earnings Call Transcript
Aug 17, 2022

CHF363.6 (+8.28%)

Earnings
Tecan Group AG at UBS Global Healthcare Conference Transcript
May 23, 2022
Full Year 2021 Tecan Group AG Earnings Call Transcript
Mar 15, 2022

CHF315 (-15.96%)

Earnings
Half Year 2021 Tecan Group AG Earnings Call Transcript
Aug 18, 2021

CHF535 (+1.33%)

Earnings
Tecan Group AG to Acquire Paramit Corp Call Transcript
Jun 24, 2021
Tecan Group AG at UBS Global Healthcare Virtual Conference Transcript
May 25, 2021
Full Year 2020 Tecan Group AG Earnings Call Transcript
Mar 16, 2021

CHF386.6 (+4.04%)

Earnings
Tecan Group AG at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Half Year 2020 Tecan Group AG Earnings Call Transcript
Aug 12, 2020

CHF396.4 (+0.92%)

Earnings
Tecan Group AG at UBS Global Healthcare Conference (Virtual) Transcript
May 19, 2020
Full Year 2019 Tecan Group AG Earnings Call Transcript
Mar 17, 2020

CHF275 (+9.91%)

Earnings
Half Year 2019 Tecan Group AG Earnings Call Transcript
Aug 15, 2019

CHF235 (-3.53%)

Earnings
Tecan Group AG Capital Markets Day Transcript
Jun 06, 2019
Tecan Group AG at UBS Global Healthcare Conference Transcript
May 21, 2019
Full Year 2018 Tecan Group AG Earnings Call Transcript
Mar 11, 2019

Earnings

Tecan Group AG at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / NTS GMT

Release Date Price: CHF328.6 (+0.18%)

Transcript

Nefu Davia JPMorgan Chase;Co.;Analyst

&-

Good morning, ladies and gentlemen. I'm [Nefu Davia], and I'm a member of the JPMorgan investment banking healthcare team. This morning, we have Achim presenting, CEO of Tecan. Over to you.

Achim von Leoprechting Tecan Group AG;CEO

Thank you very much, and good morning from my side. And yeah, thank you for your interest in this update on Tecan. Before I go into the presentation, as always, please acknowledge our Safe Harbor statement in front, which is also downloadable on the JPMorgan website.

Now we continue to live through quite dynamic times. And we, as a company, are certainly seeing specific trends and macro environments that facilitate and fuel our growth trajectory. So when looking at -- maybe for examples, we see and continue to see investments in biological discoveries. And we see an explosion of biological knowledge addressing more specific disease types around the world.

Second part is we see increasingly growing, in some areas, aging population, which means we

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.